查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1969262

成人疫苗市场：按疫苗类型、疫苗技术、给药途径、年龄层、通路和全球预测（2026-2032 年）划分

Adult Vaccines Market by Vaccine Type, Vaccine Technology, Route Of Administration, Age Group, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 190 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2025年成人疫苗市值为207.7亿美元，预计2026年将成长至225.8亿美元，复合年增长率为8.46%，预计到2032年将达到366.8亿美元。

主要市场统计数据
基准年 2025 207.7亿美元
预计年份：2026年 225.8亿美元
预测年份 2032 366.8亿美元
复合年增长率 (%) 8.46%

从策略观点看成人免疫生态系统：重点关注关键驱动因素、相关人员需求以及实证决策的基本背景。

成人免疫接种领域正经历重大变革，这场变革受到科学突破、人口结构变化和公共卫生优先事项演变的共同影响。产业、医疗服务提供者和相关人员正努力应对技术创新、患者期望和报销动态之间错综复杂的相互作用，这些因素共同决定了哪些预防策略能够有效推广。为了应对这项挑战，决策者必须平衡短期营运压力与对产品研发和生产韧性的长期投资。

对指导成人疫苗发展、供应和策略竞争重组的结构和技术转折点进行分析考察。

近年来，变革性的变化加速发生，重新定义了成人疫苗的研发、生产、分发和销售方式。核酸平台和重组技术的进步缩短了研发週期，并实现了更具针对性的免疫抗原性原性，提高了人们对疫苗研发速度和扩充性的期望。同时，数位健康和​​数据分析技术也使得针对成人族群的疫苗接种更加精准，并改善了上市后监测，从而加强了安全性监测和真实世界疗效证据的取得。

对近期美国关税政策对疫苗供应链、采购经济和战略製造选择的累积影响全面评估。

近期关税措施的累积影响波及整个疫苗供应链，波及原料采购、生产成本及分销物流。关税调整提高了配方、管瓶和低温运输耗材等某些投入品和组件的到岸成本，迫使製造商重新评估供应商合约和库存管理政策。因此，各组织更重视近岸外包、长期供应商合约和经认证的多供应商策略，以减轻贸易摩擦的影响。

我们将对疫苗类型、平台技术、给药途径、分销管道和成人年龄组进行综合細項分析，以确定策略性机会丛集。

详细的細項分析揭示了临床需求、技术成熟度和分销管道趋势的交汇点，从而创造了差异化的机会。疫苗类型包括使用灭活疫苗、mRNA疫苗、蛋白质次单元疫苗和病毒载体方法製备的COVID-19疫苗；肝炎疫苗，分为联合製剂、甲型肝炎疫苗和乙型肝炎疫苗；带状疱疹疫苗，分为欣格瑞（Shingrix）和佐斯塔瓦克斯（Zostavax）；HPV疫苗，分为9价、2000KKen气和脑膜炎。更广泛的类别包括麻疹、腮腺炎、德国麻疹（MMR）疫苗、大流行性流感疫苗、肺炎球菌疫苗（如PCV13/15/20和PPSV23）、季节性流感疫苗、百白破疫苗（包括Td变异株）和水痘製剂。这种多样性表明，产品层面的差异化仍然是决定临床定位和采购优先顺序的关键因素。

从区域观点来看，我们分析不同的医疗保健系统、管理体制和供给能力如何影响全球市场的疫苗引进和部署策略。

区域趋势正以不同的方式影响需求模式、监管方式和供应链结构。在美洲，除了商业免疫计画和私人采购管道外，大规模公共免疫计画也在进行，导致自愿性成人免疫宣传活动和雇主主导的免疫计画并存，形成了一种复杂的局面。在欧洲和中东及非洲，监管协调和多元化公共资金模式的努力正在影响疫苗采购计画和新疫苗技术的应用，而低温运输基础设施的差异则继续推动优先投资。

对决定成人疫苗研发和供应领域领导地位的竞争定位、策略联盟和营运能力进行全面的产业分析。

成人疫苗领域的竞争动态由成熟的跨国公司、新兴生物技术专家和能够快速扩大生产规模的契约製造组织 (CMO) 共同塑造。领先的製药和生物技术公司正在推动平台多元化，致力于开发下一代疫苗结构并优化现有产品的生命週期管理。平台创新者与大型生产者之间的合作日益增多，将科学研究的弹性与生产的可靠性结合。这些合作正变得越来越具有战略意义，其范围已从简单的授权授权扩展到共同开发、区域生产协议和风险共用机制。

为製造商、支付方和公共卫生领导者提供切实可行的策略建议，以增强韧性、加快部署并优化成人免疫接种效果。

产业界和政策制定者必须采取切实可行的多管齐下的策略，将科学潜力转化为群体层面的保护。首先，应优先投资模组化製造和区域产能合作，以降低贸易伙伴关係波动风险，并在需求激增时快速产能扩张。其次，应整合技术蓝图，平衡短期供给需求与长期平台投资，确保从研发早期阶段就使临床策略与监理策略保持一致。第三，应透过创造强调真实世界疗效、安全性和卫生经济价值的证据，加强与商业部门和支付者的合作。

为了确保研究结果的可靠性，我们将对我们的研究设计进行透明的解释，该设计融合了定性访谈、二手证据整合和交叉检验的分析框架。

支持这些发现的研究结合了定性专家访谈、有针对性的二手文献整合以及结构化的检验练习。关键投入包括与临床负责人、供应链经理、监管专家和支付方进行磋商，以了解实际营运中的限制和策略重点。二手分析整合了同行评审的科学文献、监管指导文件和公共卫生政策声明，以确保技术和监管方面的观察结果是基于最新证据。

本文简要概述了决定成人免疫计划扩展及其永续性。

成人疫苗领域既充满机会也面临挑战。儘管科技进步拓展了预防干预措施的选择范围，但从创新到有效性的转化需要生产、监管、支付方和交付系统等各环节的协调努力。在技​​术采纳、通路优化以及区域生产结构韧性等方面的策略选择，将决定哪些项目能够实现永续规模化，哪些项目将面临持续的挑战。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：成人疫苗市场：依疫苗类型划分

  • 冠状病毒感染疾病（COVID-19）
    • 失活
    • mRNA
    • 蛋白质次单元
    • 病毒载体
  • 肝炎
    • 联合疫苗
    • 甲型肝炎
    • B型肝炎
  • 带状疱疹
    • 定序
    • 佐斯塔瓦茨
  • HPV
    • 九价
    • 二价
    • 四价
  • 脑膜炎奈瑟菌
    • MenACWY
    • B族脑膜炎双球菌
  • MMR
  • 大流行性流感
  • 肺炎球菌
    • PCV13
    • PCV15
    • PCV20
    • PPSV23
  • 季节性流感
  • Tdap
    • Td
    • Tdap
  • 水痘

第九章：成人疫苗市场：依疫苗技术划分

  • 组合型
  • DNA
    • 遗传编码
    • 质体DNA
  • 失活
  • 活病毒疫苗
  • mRNA
    • 核苷修饰型
    • 自放大
  • 重组
  • 类毒素
    • 白喉类毒素
    • 破伤风类毒素
  • 病毒载体
    • 非复製型
    • 复製类型

第十章 成人疫苗市场：依给药途径划分

  • 皮内给药
  • 肌肉内部
  • 鼻腔
  • 口服
  • 皮下注射

第十一章 成人疫苗市场：依年龄组别划分

  • 18-30岁
  • 31至45岁
  • 46至60岁
  • 61岁或以上

第十二章 成人疫苗市场：依通路划分

  • 诊所
  • 医院
  • 网路药房
  • 公共卫生中心
  • 零售药房

第十三章 成人疫苗市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章 成人疫苗市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章 成人疫苗市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章：美国：成人疫苗市场

第十七章 中国：成人疫苗市场

第十八章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Bavarian Nordic A/S
  • CSL Limited
  • GlaxoSmithKline plc
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Moderna, Inc.
  • Novavax, Inc.
  • Novavax, Inc.
  • Pfizer Inc.
  • Sanofi SA
  • Takeda Pharmaceutical Company Ltd.
  • Valneva SE
Product Code: MRR-535C6291878F

The Adult Vaccines Market was valued at USD 20.77 billion in 2025 and is projected to grow to USD 22.58 billion in 2026, with a CAGR of 8.46%, reaching USD 36.68 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 20.77 billion
Estimated Year [2026] USD 22.58 billion
Forecast Year [2032] USD 36.68 billion
CAGR (%) 8.46%

A strategic orientation to the adult immunization ecosystem highlighting key drivers, stakeholder imperatives, and the essential context for evidence-based decision-making

The adult immunization environment is at a pivotal moment, shaped by scientific breakthroughs, demographic shifts, and evolving public health priorities. Stakeholders across industry, healthcare delivery, and policy are navigating a complex interplay of technological innovation, patient expectations, and reimbursement dynamics that together determine which prevention strategies will scale effectively. In response, decision-makers must reconcile near-term operational pressures with longer-term investments in product development and manufacturing resilience.

This executive summary synthesizes core trends and practical implications for leaders focused on adult vaccines. It frames the competitive landscape through the lens of vaccine technology diversity, route of administration preferences, distribution channel evolution, and age-segmented demand patterns. In doing so, it clarifies the strategic choices that will govern portfolio prioritization, partnerships, and supply continuity over the coming strategic planning cycles. Ultimately, this introduction sets the context for subsequent sections that unpack transformative shifts, regulatory and trade impacts, segmentation-driven opportunity, and region-specific dynamics.

An analytical exploration of the structural and technological inflection points reshaping adult vaccine development, delivery, and strategic competitive positioning

Recent years have catalyzed transformative shifts that are redefining how adult vaccines are developed, manufactured, distributed, and adopted. Advances in nucleic acid platforms and recombinant technologies have shortened development timelines and enabled more targeted immunogenic profiles, which in turn has raised expectations for speed and scalability. Parallel to these scientific advances, digital health and data analytics are enabling more precise targeting of adult cohorts and improved post-market surveillance, strengthening safety monitoring and real-world effectiveness evidence.

Concurrently, supply chain resilience has assumed strategic importance, prompting firms to reassess sourcing strategies, diversify manufacturing footprints, and pursue flexible fill-finish capacity. Regulatory pathways have evolved to balance expedited access with rigorous safety standards, increasing the importance of proactive regulatory engagement and robust clinical evidence planning. Taken together, these shifts are creating new competitive arenas where agility in technology adoption and partnership orchestration will determine which players capture sustained value.

A comprehensive assessment of how recent United States tariff policies have cumulatively affected vaccine supply chains, procurement economics, and strategic manufacturing choices

The cumulative impact of recent tariff actions has reverberated through vaccine supply chains, affecting raw material sourcing, manufacturing economics, and distribution logistics. Tariff adjustments have increased landed costs for certain inputs and components used in formulation, vials, and cold chain consumables, prompting manufacturers to reassess supplier agreements and inventory policies. As a result, organizations are placing greater emphasis on nearshoring, long-term supplier contracts, and qualified multiple-supplier strategies to mitigate exposure to trade frictions.

Moreover, the tariff environment has influenced capital allocation decisions for production capacity expansion and strategic stockholding. In response, some stakeholders have accelerated investments in domestic fill-and-finish capacity and technology transfer programs while others have renegotiated commercial terms to preserve margins. Regulatory coordination and diplomatic channels have become more salient in advanced planning, since tariff-induced cost pressures can translate into procurement tender dynamics and reimbursement negotiations. Looking ahead, adaptive sourcing, diversified logistics arrangements, and proactive regulatory engagement are core mitigation levers that can preserve continuity of supply and protect affordability for adult immunization programs.

An integrated segmentation analysis that aligns vaccine types, platform technologies, administration routes, distribution channels, and adult age cohorts to reveal strategic opportunity clusters

A granular view of segmentation reveals where clinical need, technology readiness, and delivery channel dynamics converge to create differentiated opportunities. By vaccine type, the landscape spans Covid 19 vaccines analyzed across inactivated, mRNA, protein subunit, and viral vector approaches; hepatitis vaccines parsed into combined formulations, hepatitis A, and hepatitis B; herpes zoster vaccines differentiated by Shingrix and Zostavax; HPV products categorized as 9-valent, bivalent, and quadrivalent; meningococcal vaccines distinguished between MenACWY and MenB; and a broader set including MMR, pandemic influenza, pneumococcal options such as PCV13, PCV15, PCV20, and PPSV23, seasonal influenza, Tdap with Td variants, and varicella formulations. This spectrum indicates that product-level differentiation remains a primary determinant of clinical positioning and procurement preference.

Based on vaccine technology, the field encompasses conjugate approaches, DNA platforms split into gene-encoded and plasmid DNA, inactivated formulations, live attenuated options, mRNA platforms including nucleoside-modified and self-amplifying variants, recombinant subunit technologies, toxoid categories such as diphtheria and tetanus toxoids, and viral vector systems that are either non-replicating or replicating. Route of administration also matters, with intradermal, intramuscular, intranasal, oral, and subcutaneous delivery routes affecting patient acceptance, administration costs, and cold chain considerations. Distribution channels range from clinics, hospitals, and public health centers to retail pharmacies and online pharmacies, each with distinct procurement cycles, refrigeration infrastructures, and patient touchpoints. Finally, age segmentation among adults-18 to 30, 31 to 45, 46 to 60, and 61 and above-drives clinical priorities, uptake incentives, and communication strategies. When layered together, these segmentation axes enable nuanced targeting of clinical value propositions, pricing models, and rollout sequencing.

A regional perspective that deciphers how distinct healthcare systems, regulatory regimes, and supply capabilities shape vaccine adoption and deployment strategies across global markets

Regional dynamics are shaping demand patterns, regulatory approaches, and supply chain architectures in distinct ways. In the Americas, commercial vaccination programs and private-sector procurement channels are complemented by large public immunization initiatives, producing a mixed landscape where voluntary adult vaccination campaigns coexist with employer-sponsored programs. Across Europe, Middle East & Africa, regulatory harmonization efforts and varying public financing models influence procurement timelines and the adoption of newer vaccine technologies, while disparities in cold chain infrastructure continue to drive priority investments.

In Asia-Pacific, rapid manufacturing scale-up, strong domestic industry participation, and targeted government immunization campaigns have accelerated adoption curves for a range of adult vaccines. These regional patterns underscore the importance of aligning portfolio strategies with local regulatory pathways, payment mechanisms, and distribution networks. Strategic partnerships, regional manufacturing collaborations, and context-sensitive communication campaigns can bridge gaps between global product development and local delivery capabilities, thereby improving access and program sustainability.

An industry-focused synthesis of competitive positioning, strategic alliances, and the operational capabilities that determine leadership in adult vaccine development and supply

Competitive dynamics in the adult vaccine arena are driven by a mix of established multinationals, emerging biotech specialists, and contract manufacturing organizations that enable rapid scale. Leading pharmaceutical and biotech companies are advancing platform diversification, pursuing both next-generation vaccine constructs and lifecycle management of legacy products. Partnerships between platform innovators and large-scale manufacturers have proliferated, combining scientific agility with production reliability. These collaborations are increasingly strategic, extending beyond licensing to encompass co-development, regional manufacturing agreements, and shared risk frameworks.

Concurrently, contract development and manufacturing organizations have become critical enablers, offering flexible capacity, fill-finish services, and regulatory support for technology transfers. Competitive advantage is increasingly determined by integrated capabilities across R&D, regulatory affairs, and global distribution networks, along with the ability to demonstrate real-world effectiveness and cost-effectiveness to payers. Companies that can align clinical differentiation with operational resilience and payer-aligned pricing strategies are best positioned to sustain growth in adult vaccination programs.

Actionable strategic recommendations for manufacturers, payers, and public health leaders to strengthen resilience, accelerate adoption, and optimize adult immunization outcomes

Leaders in industry and policy must adopt pragmatic, multi-dimensional strategies to translate scientific promise into population-level protection. First, prioritize modular manufacturing investments and regional capacity partnerships to reduce exposure to trade policy volatility and to enable rapid scale-up when demand surges. Second, integrate technology roadmaps that balance near-term delivery requirements with longer-term platform investments, ensuring that clinical and regulatory strategies align from the earliest development stages. Third, strengthen commercial and payer engagement through evidence generation that emphasizes real-world effectiveness, safety, and health economic value.

In addition, refine distribution partnerships by aligning cold chain capabilities with channel-specific needs and by exploring hybrid models that leverage clinical sites, retail pharmacies, and validated online channels to maximize reach. Enhance patient-centered communication strategies that are tailored by age cohort and risk profile, and embed digital tools to facilitate scheduling, reminders, and adverse event reporting. Finally, institutionalize scenario planning that incorporates trade policy shifts, supply disruptions, and regulatory acceleration, so that contingency actions can be executed with minimal disruption to program continuity.

A transparent explanation of the research design that integrates qualitative interviews, secondary evidence synthesis, and cross-validated analytical frameworks to ensure credible insights

The research underpinning these insights combined qualitative expert interviews, targeted secondary literature synthesis, and structured validation exercises. Primary inputs included consultations with clinical leaders, supply chain managers, regulatory specialists, and payers to capture real-world operational constraints and strategic priorities. Secondary analysis synthesized peer-reviewed science, regulatory guidance documents, and public health policy statements to ensure that technological and regulatory observations were grounded in current evidence.

Findings were triangulated through cross-validation with commercial leaders and program implementers to stress-test assumptions and identify practical mitigation options. Segmentation frameworks were mapped by aligning vaccine types, technology platforms, administration routes, distribution channels, and adult age cohorts to observed deployment patterns. Throughout the methodology, emphasis was placed on transparency of assumptions, reproducibility of analytical steps, and clear delineation between evidence-based conclusions and scenario-based implications.

A concise synthesis of the strategic imperatives and operational levers that will determine success in expanding adult immunization coverage and program sustainability

The adult vaccines landscape is defined by simultaneous opportunity and complexity: scientific advances have expanded the feasible portfolio of preventative interventions, but the translation from innovation to impact requires coordinated action across manufacturing, regulatory, payer, and delivery systems. Strategic choices around technology adoption, distribution channel optimization, and regional manufacturing resilience will determine which programs achieve sustainable scale and which face persistent barriers.

To navigate this environment, stakeholders must prioritize adaptable supply strategies, evidence-driven payer engagement, and targeted communication to adult cohorts. When executed coherently, these elements can accelerate uptake, preserve affordability, and strengthen public health preparedness. The insights in this summary are designed to assist leaders in aligning near-term operational decisions with long-term value creation for adult immunization programs.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Adult Vaccines Market, by Vaccine Type

  • 8.1. Covid 19
    • 8.1.1. Inactivated
    • 8.1.2. Mrna
    • 8.1.3. Protein Subunit
    • 8.1.4. Viral Vector
  • 8.2. Hepatitis
    • 8.2.1. Combined
    • 8.2.2. Hepatitis A
    • 8.2.3. Hepatitis B
  • 8.3. Herpes Zoster
    • 8.3.1. Shingrix
    • 8.3.2. Zostavax
  • 8.4. Hpv
    • 8.4.1. 9-Valent
    • 8.4.2. Bivalent
    • 8.4.3. Quadrivalent
  • 8.5. Meningococcal
    • 8.5.1. MenACWY
    • 8.5.2. MenB
  • 8.6. Mmr
  • 8.7. Pandemic Influenza
  • 8.8. Pneumococcal
    • 8.8.1. Pcv13
    • 8.8.2. Pcv15
    • 8.8.3. Pcv20
    • 8.8.4. Ppsv23
  • 8.9. Seasonal Influenza
  • 8.10. Tdap
    • 8.10.1. Td
    • 8.10.2. Tdap
  • 8.11. Varicella

9. Adult Vaccines Market, by Vaccine Technology

  • 9.1. Conjugate
  • 9.2. Dna
    • 9.2.1. Gene Encoded
    • 9.2.2. Plasmid Dna
  • 9.3. Inactivated
  • 9.4. Live Attenuated
  • 9.5. Mrna
    • 9.5.1. Nucleoside Modified
    • 9.5.2. Self Amplifying
  • 9.6. Recombinant
  • 9.7. Toxoid
    • 9.7.1. Diphtheria Toxoid
    • 9.7.2. Tetanus Toxoid
  • 9.8. Viral Vector
    • 9.8.1. Non Replicating
    • 9.8.2. Replicating

10. Adult Vaccines Market, by Route Of Administration

  • 10.1. Intradermal
  • 10.2. Intramuscular
  • 10.3. Intranasal
  • 10.4. Oral
  • 10.5. Subcutaneous

11. Adult Vaccines Market, by Age Group

  • 11.1. 18 To 30
  • 11.2. 31 To 45
  • 11.3. 46 To 60
  • 11.4. 61 And Above

12. Adult Vaccines Market, by Distribution Channel

  • 12.1. Clinics
  • 12.2. Hospitals
  • 12.3. Online Pharmacies
  • 12.4. Public Health Centers
  • 12.5. Retail Pharmacies

13. Adult Vaccines Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Adult Vaccines Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Adult Vaccines Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Adult Vaccines Market

17. China Adult Vaccines Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Bavarian Nordic A/S
  • 18.6. CSL Limited
  • 18.7. GlaxoSmithKline plc
  • 18.8. Johnson & Johnson
  • 18.9. Merck & Co., Inc.
  • 18.10. Moderna, Inc.
  • 18.11. Novavax, Inc.
  • 18.12. Novavax, Inc.
  • 18.13. Pfizer Inc.
  • 18.14. Sanofi S.A.
  • 18.15. Takeda Pharmaceutical Company Ltd.
  • 18.16. Valneva SE

LIST OF FIGURES

  • FIGURE 1. GLOBAL ADULT VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ADULT VACCINES MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL ADULT VACCINES MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL ADULT VACCINES MARKET SIZE, BY VACCINE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL ADULT VACCINES MARKET SIZE, BY VACCINE TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ADULT VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL ADULT VACCINES MARKET SIZE, BY AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ADULT VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL ADULT VACCINES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ADULT VACCINES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL ADULT VACCINES MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES ADULT VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA ADULT VACCINES MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL ADULT VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL ADULT VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL ADULT VACCINES MARKET SIZE, BY COVID 19, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL ADULT VACCINES MARKET SIZE, BY COVID 19, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL ADULT VACCINES MARKET SIZE, BY COVID 19, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL ADULT VACCINES MARKET SIZE, BY COVID 19, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL ADULT VACCINES MARKET SIZE, BY INACTIVATED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL ADULT VACCINES MARKET SIZE, BY INACTIVATED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL ADULT VACCINES MARKET SIZE, BY INACTIVATED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL ADULT VACCINES MARKET SIZE, BY MRNA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL ADULT VACCINES MARKET SIZE, BY MRNA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL ADULT VACCINES MARKET SIZE, BY MRNA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL ADULT VACCINES MARKET SIZE, BY PROTEIN SUBUNIT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL ADULT VACCINES MARKET SIZE, BY PROTEIN SUBUNIT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL ADULT VACCINES MARKET SIZE, BY PROTEIN SUBUNIT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL ADULT VACCINES MARKET SIZE, BY VIRAL VECTOR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL ADULT VACCINES MARKET SIZE, BY VIRAL VECTOR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL ADULT VACCINES MARKET SIZE, BY VIRAL VECTOR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL ADULT VACCINES MARKET SIZE, BY HEPATITIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL ADULT VACCINES MARKET SIZE, BY HEPATITIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL ADULT VACCINES MARKET SIZE, BY HEPATITIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL ADULT VACCINES MARKET SIZE, BY HEPATITIS, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL ADULT VACCINES MARKET SIZE, BY COMBINED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL ADULT VACCINES MARKET SIZE, BY COMBINED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL ADULT VACCINES MARKET SIZE, BY COMBINED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL ADULT VACCINES MARKET SIZE, BY HEPATITIS A, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL ADULT VACCINES MARKET SIZE, BY HEPATITIS A, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL ADULT VACCINES MARKET SIZE, BY HEPATITIS A, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL ADULT VACCINES MARKET SIZE, BY HEPATITIS B, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL ADULT VACCINES MARKET SIZE, BY HEPATITIS B, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL ADULT VACCINES MARKET SIZE, BY HEPATITIS B, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL ADULT VACCINES MARKET SIZE, BY HERPES ZOSTER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL ADULT VACCINES MARKET SIZE, BY HERPES ZOSTER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL ADULT VACCINES MARKET SIZE, BY HERPES ZOSTER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL ADULT VACCINES MARKET SIZE, BY HERPES ZOSTER, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL ADULT VACCINES MARKET SIZE, BY SHINGRIX, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL ADULT VACCINES MARKET SIZE, BY SHINGRIX, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL ADULT VACCINES MARKET SIZE, BY SHINGRIX, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL ADULT VACCINES MARKET SIZE, BY ZOSTAVAX, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL ADULT VACCINES MARKET SIZE, BY ZOSTAVAX, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL ADULT VACCINES MARKET SIZE, BY ZOSTAVAX, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL ADULT VACCINES MARKET SIZE, BY HPV, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL ADULT VACCINES MARKET SIZE, BY HPV, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL ADULT VACCINES MARKET SIZE, BY HPV, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL ADULT VACCINES MARKET SIZE, BY HPV, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL ADULT VACCINES MARKET SIZE, BY 9-VALENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL ADULT VACCINES MARKET SIZE, BY 9-VALENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL ADULT VACCINES MARKET SIZE, BY 9-VALENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL ADULT VACCINES MARKET SIZE, BY BIVALENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL ADULT VACCINES MARKET SIZE, BY BIVALENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL ADULT VACCINES MARKET SIZE, BY BIVALENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL ADULT VACCINES MARKET SIZE, BY QUADRIVALENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL ADULT VACCINES MARKET SIZE, BY QUADRIVALENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL ADULT VACCINES MARKET SIZE, BY QUADRIVALENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL ADULT VACCINES MARKET SIZE, BY MENINGOCOCCAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL ADULT VACCINES MARKET SIZE, BY MENINGOCOCCAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL ADULT VACCINES MARKET SIZE, BY MENINGOCOCCAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL ADULT VACCINES MARKET SIZE, BY MENINGOCOCCAL, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL ADULT VACCINES MARKET SIZE, BY MENACWY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL ADULT VACCINES MARKET SIZE, BY MENACWY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL ADULT VACCINES MARKET SIZE, BY MENACWY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL ADULT VACCINES MARKET SIZE, BY MENB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL ADULT VACCINES MARKET SIZE, BY MENB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL ADULT VACCINES MARKET SIZE, BY MENB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL ADULT VACCINES MARKET SIZE, BY MMR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL ADULT VACCINES MARKET SIZE, BY MMR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL ADULT VACCINES MARKET SIZE, BY MMR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL ADULT VACCINES MARKET SIZE, BY PANDEMIC INFLUENZA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL ADULT VACCINES MARKET SIZE, BY PANDEMIC INFLUENZA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL ADULT VACCINES MARKET SIZE, BY PANDEMIC INFLUENZA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL ADULT VACCINES MARKET SIZE, BY PNEUMOCOCCAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL ADULT VACCINES MARKET SIZE, BY PNEUMOCOCCAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL ADULT VACCINES MARKET SIZE, BY PNEUMOCOCCAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL ADULT VACCINES MARKET SIZE, BY PNEUMOCOCCAL, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL ADULT VACCINES MARKET SIZE, BY PCV13, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL ADULT VACCINES MARKET SIZE, BY PCV13, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL ADULT VACCINES MARKET SIZE, BY PCV13, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL ADULT VACCINES MARKET SIZE, BY PCV15, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL ADULT VACCINES MARKET SIZE, BY PCV15, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL ADULT VACCINES MARKET SIZE, BY PCV15, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL ADULT VACCINES MARKET SIZE, BY PCV20, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL ADULT VACCINES MARKET SIZE, BY PCV20, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL ADULT VACCINES MARKET SIZE, BY PCV20, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL ADULT VACCINES MARKET SIZE, BY PPSV23, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL ADULT VACCINES MARKET SIZE, BY PPSV23, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL ADULT VACCINES MARKET SIZE, BY PPSV23, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL ADULT VACCINES MARKET SIZE, BY SEASONAL INFLUENZA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL ADULT VACCINES MARKET SIZE, BY SEASONAL INFLUENZA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL ADULT VACCINES MARKET SIZE, BY SEASONAL INFLUENZA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL ADULT VACCINES MARKET SIZE, BY TDAP, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL ADULT VACCINES MARKET SIZE, BY TDAP, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL ADULT VACCINES MARKET SIZE, BY TDAP, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL ADULT VACCINES MARKET SIZE, BY TDAP, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL ADULT VACCINES MARKET SIZE, BY TD, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL ADULT VACCINES MARKET SIZE, BY TD, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL ADULT VACCINES MARKET SIZE, BY TD, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL ADULT VACCINES MARKET SIZE, BY TDAP, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL ADULT VACCINES MARKET SIZE, BY TDAP, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL ADULT VACCINES MARKET SIZE, BY TDAP, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL ADULT VACCINES MARKET SIZE, BY VARICELLA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL ADULT VACCINES MARKET SIZE, BY VARICELLA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL ADULT VACCINES MARKET SIZE, BY VARICELLA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL ADULT VACCINES MARKET SIZE, BY VACCINE TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL ADULT VACCINES MARKET SIZE, BY CONJUGATE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL ADULT VACCINES MARKET SIZE, BY CONJUGATE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL ADULT VACCINES MARKET SIZE, BY CONJUGATE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL ADULT VACCINES MARKET SIZE, BY DNA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL ADULT VACCINES MARKET SIZE, BY DNA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL ADULT VACCINES MARKET SIZE, BY DNA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL ADULT VACCINES MARKET SIZE, BY DNA, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL ADULT VACCINES MARKET SIZE, BY GENE ENCODED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL ADULT VACCINES MARKET SIZE, BY GENE ENCODED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL ADULT VACCINES MARKET SIZE, BY GENE ENCODED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL ADULT VACCINES MARKET SIZE, BY PLASMID DNA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL ADULT VACCINES MARKET SIZE, BY PLASMID DNA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL ADULT VACCINES MARKET SIZE, BY PLASMID DNA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL ADULT VACCINES MARKET SIZE, BY INACTIVATED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL ADULT VACCINES MARKET SIZE, BY INACTIVATED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL ADULT VACCINES MARKET SIZE, BY INACTIVATED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL ADULT VACCINES MARKET SIZE, BY LIVE ATTENUATED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL ADULT VACCINES MARKET SIZE, BY LIVE ATTENUATED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL ADULT VACCINES MARKET SIZE, BY LIVE ATTENUATED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL ADULT VACCINES MARKET SIZE, BY MRNA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL ADULT VACCINES MARKET SIZE, BY MRNA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL ADULT VACCINES MARKET SIZE, BY MRNA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL ADULT VACCINES MARKET SIZE, BY MRNA, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL ADULT VACCINES MARKET SIZE, BY NUCLEOSIDE MODIFIED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL ADULT VACCINES MARKET SIZE, BY NUCLEOSIDE MODIFIED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL ADULT VACCINES MARKET SIZE, BY NUCLEOSIDE MODIFIED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL ADULT VACCINES MARKET SIZE, BY SELF AMPLIFYING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL ADULT VACCINES MARKET SIZE, BY SELF AMPLIFYING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL ADULT VACCINES MARKET SIZE, BY SELF AMPLIFYING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL ADULT VACCINES MARKET SIZE, BY RECOMBINANT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL ADULT VACCINES MARKET SIZE, BY RECOMBINANT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL ADULT VACCINES MARKET SIZE, BY RECOMBINANT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 136. GLOBAL ADULT VACCINES MARKET SIZE, BY TOXOID, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL ADULT VACCINES MARKET SIZE, BY TOXOID, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL ADULT VACCINES MARKET SIZE, BY TOXOID, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 139. GLOBAL ADULT VACCINES MARKET SIZE, BY TOXOID, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL ADULT VACCINES MARKET SIZE, BY DIPHTHERIA TOXOID, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 141. GLOBAL ADULT VACCINES MARKET SIZE, BY DIPHTHERIA TOXOID, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 142. GLOBAL ADULT VACCINES MARKET SIZE, BY DIPHTHERIA TOXOID, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 143. GLOBAL ADULT VACCINES MARKET SIZE, BY TETANUS TOXOID, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 144. GLOBAL ADULT VACCINES MARKET SIZE, BY TETANUS TOXOID, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 145. GLOBAL ADULT VACCINES MARKET SIZE, BY TETANUS TOXOID, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 146. GLOBAL ADULT VACCINES MARKET SIZE, BY VIRAL VECTOR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 147. GLOBAL ADULT VACCINES MARKET SIZE, BY VIRAL VECTOR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 148. GLOBAL ADULT VACCINES MARKET SIZE, BY VIRAL VECTOR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 149. GLOBAL ADULT VACCINES MARKET SIZE, BY VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 150. GLOBAL ADULT VACCINES MARKET SIZE, BY NON REPLICATING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 151. GLOBAL ADULT VACCINES MARKET SIZE, BY NON REPLICATING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 152. GLOBAL ADULT VACCINES MARKET SIZE, BY NON REPLICATING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 153. GLOBAL ADULT VACCINES MARKET SIZE, BY REPLICATING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 154. GLOBAL ADULT VACCINES MARKET SIZE, BY REPLICATING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 155. GLOBAL ADULT VACCINES MARKET SIZE, BY REPLICATING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 156. GLOBAL ADULT VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 157. GLOBAL ADULT VACCINES MARKET SIZE, BY INTRADERMAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 158. GLOBAL ADULT VACCINES MARKET SIZE, BY INTRADERMAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 159. GLOBAL ADULT VACCINES MARKET SIZE, BY INTRADERMAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 160. GLOBAL ADULT VACCINES MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 161. GLOBAL ADULT VACCINES MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 162. GLOBAL ADULT VACCINES MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 163. GLOBAL ADULT VACCINES MARKET SIZE, BY INTRANASAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 164. GLOBAL ADULT VACCINES MARKET SIZE, BY INTRANASAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 165. GLOBAL ADULT VACCINES MARKET SIZE, BY INTRANASAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 166. GLOBAL ADULT VACCINES MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 167. GLOBAL ADULT VACCINES MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 168. GLOBAL ADULT VACCINES MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 169. GLOBAL ADULT VACCINES MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 170. GLOBAL ADULT VACCINES MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 171. GLOBAL ADULT VACCINES MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 172. GLOBAL ADULT VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 173. GLOBAL ADULT VACCINES MARKET SIZE, BY 18 TO 30, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 174. GLOBAL ADULT VACCINES MARKET SIZE, BY 18 TO 30, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 175. GLOBAL ADULT VACCINES MARKET SIZE, BY 18 TO 30, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 176. GLOBAL ADULT VACCINES MARKET SIZE, BY 31 TO 45, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 177. GLOBAL ADULT VACCINES MARKET SIZE, BY 31 TO 45, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 178. GLOBAL ADULT VACCINES MARKET SIZE, BY 31 TO 45, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 179. GLOBAL ADULT VACCINES MARKET SIZE, BY 46 TO 60, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 180. GLOBAL ADULT VACCINES MARKET SIZE, BY 46 TO 60, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 181. GLOBAL ADULT VACCINES MARKET SIZE, BY 46 TO 60, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 182. GLOBAL ADULT VACCINES MARKET SIZE, BY 61 AND ABOVE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 183. GLOBAL ADULT VACCINES MARKET SIZE, BY 61 AND ABOVE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 184. GLOBAL ADULT VACCINES MARKET SIZE, BY 61 AND ABOVE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 185. GLOBAL ADULT VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 186. GLOBAL ADULT VACCINES MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 187. GLOBAL ADULT VACCINES MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 188. GLOBAL ADULT VACCINES MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 189. GLOBAL ADULT VACCINES MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 190. GLOBAL ADULT VACCINES MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 191. GLOBAL ADULT VACCINES MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 192. GLOBAL ADULT VACCINES MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 193. GLOBAL ADULT VACCINES MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 194. GLOBAL ADULT VACCINES MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 195. GLOBAL ADULT VACCINES MARKET SIZE, BY PUBLIC HEALTH CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 196. GLOBAL ADULT VACCINES MARKET SIZE, BY PUBLIC HEALTH CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 197. GLOBAL ADULT VACCINES MARKET SIZE, BY PUBLIC HEALTH CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 198. GLOBAL ADULT VACCINES MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 199. GLOBAL ADULT VACCINES MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 200. GLOBAL ADULT VACCINES MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 201. GLOBAL ADULT VACCINES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 202. AMERICAS ADULT VACCINES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 203. AMERICAS ADULT VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 204. AMERICAS ADULT VACCINES MARKET SIZE, BY COVID 19, 2018-2032 (USD MILLION)
  • TABLE 205. AMERICAS ADULT VACCINES MARKET SIZE, BY HEPATITIS, 2018-2032 (USD MILLION)
  • TABLE 206. AMERICAS ADULT VACCINES MARKET SIZE, BY HERPES ZOSTER, 2018-2032 (USD MILLION)
  • TABLE 207. AMERICAS ADULT VACCINES MARKET SIZE, BY HPV, 2018-2032 (USD MILLION)
  • TABLE 208. AMERICAS ADULT VACCINES MARKET SIZE, BY MENINGOCOCCAL, 2018-2032 (USD MILLION)
  • TABLE 209. AMERICAS ADULT VACCINES MARKET SIZE, BY PNEUMOCOCCAL, 2018-2032 (USD MILLION)
  • TABLE 210. AMERICAS ADULT VACCINES MARKET SIZE, BY TDAP, 2018-2032 (USD MILLION)
  • TABLE 211. AMERICAS ADULT VACCINES MARKET SIZE, BY VACCINE TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 212. AMERICAS ADULT VACCINES MARKET SIZE, BY DNA, 2018-2032 (USD MILLION)
  • TABLE 213. AMERICAS ADULT VACCINES MARKET SIZE, BY MRNA, 2018-2032 (USD MILLION)
  • TABLE 214. AMERICAS ADULT VACCINES MARKET SIZE, BY TOXOID, 2018-2032 (USD MILLION)
  • TABLE 215. AMERICAS ADULT VACCINES MARKET SIZE, BY VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 216. AMERICAS ADULT VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 217. AMERICAS ADULT VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 218. AMERICAS ADULT VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 219. NORTH AMERICA ADULT VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 220. NORTH AMERICA ADULT VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 221. NORTH AMERICA ADULT VACCINES MARKET SIZE, BY COVID 19, 2018-2032 (USD MILLION)
  • TABLE 222. NORTH AMERICA ADULT VACCINES MARKET SIZE, BY HEPATITIS, 2018-2032 (USD MILLION)
  • TABLE 223. NORTH AMERICA ADULT VACCINES MARKET SIZE, BY HERPES ZOSTER, 2018-2032 (USD MILLION)
  • TABLE 224. NORTH AMERICA ADULT VACCINES MARKET SIZE, BY HPV, 2018-2032 (USD MILLION)
  • TABLE 225. NORTH AMERICA ADULT VACCINES MARKET SIZE, BY MENINGOCOCCAL, 2018-2032 (USD MILLION)
  • TABLE 226. NORTH AMERICA ADULT VACCINES MARKET SIZE, BY PNEUMOCOCCAL, 2018-2032 (USD MILLION)
  • TABLE 227. NORTH AMERICA ADULT VACCINES MARKET SIZE, BY TDAP, 2018-2032 (USD MILLION)
  • TABLE 228. NORTH AMERICA ADULT VACCINES MARKET SIZE, BY VACCINE TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 229. NORTH AMERICA ADULT VACCINES MARKET SIZE, BY DNA, 2018-2032 (USD MILLION)
  • TABLE 230. NORTH AMERICA ADULT VACCINES MARKET SIZE, BY MRNA, 2018-2032 (USD MILLION)
  • TABLE 231. NORTH AMERICA ADULT VACCINES MARKET SIZE, BY TOXOID, 2018-2032 (USD MILLION)
  • TABLE 232. NORTH AMERICA ADULT VACCINES MARKET SIZE, BY VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 233. NORTH AMERICA ADULT VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 234. NORTH AMERICA ADULT VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 235. NORTH AMERICA ADULT VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 236. LATIN AMERICA ADULT VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 237. LATIN AMERICA ADULT VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 238. LATIN AMERICA ADULT VACCINES MARKET SIZE, BY COVID 19, 2018-2032 (USD MILLION)
  • TABLE 239. LATIN AMERICA ADULT VACCINES MARKET SIZE, BY HEPATITIS, 2018-2032 (USD MILLION)
  • TABLE 240. LATIN AMERICA ADULT VACCINES MARKET SIZE, BY HERPES ZOSTER, 2018-2032 (USD MILLION)
  • TABLE 241. LATIN AMERICA ADULT VACCINES MARKET SIZE, BY HPV, 2018-2032 (USD MILLION)
  • TABLE 242. LATIN AMERICA ADULT VACCINES MARKET SIZE, BY MENINGOCOCCAL, 2018-2032 (USD MILLION)
  • TABLE 243. LATIN AMERICA ADULT VACCINES MARKET SIZE, BY PNEUMOCOCCAL, 2018-2032 (USD MILLION)
  • TABLE 244. LATIN AMERICA ADULT VACCINES MARKET SIZE, BY TDAP, 2018-2032 (USD MILLION)
  • TABLE 245. LATIN AMERICA ADULT VACCINES MARKET SIZE, BY VACCINE TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 246. LATIN AMERICA ADULT VACCINES MARKET SIZE, BY DNA, 2018-2032 (USD MILLION)
  • TABLE 247. LATIN AMERICA ADULT VACCINES MARKET SIZE, BY MRNA, 2018-2032 (USD MILLION)
  • TABLE 248. LATIN AMERICA ADULT VACCINES MARKET SIZE, BY TOXOID, 2018-2032 (USD MILLION)
  • TABLE 249. LATIN AMERICA ADULT VACCINES MARKET SIZE, BY VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 250. LATIN AMERICA ADULT VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 251. LATIN AMERICA ADULT VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 252. LATIN AMERICA ADULT VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 253. EUROPE, MIDDLE EAST & AFRICA ADULT VACCINES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 254. EUROPE, MIDDLE EAST & AFRICA ADULT VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 255. EUROPE, MIDDLE EAST & AFRICA ADULT VACCINES MARKET SIZE, BY COVID 19, 2018-2032 (USD MILLION)
  • TABLE 256. EUROPE, MIDDLE EAST & AFRICA ADULT VACCINES MARKET SIZE, BY HEPATITIS, 2018-2032 (USD MILLION)
  • TABLE 257. EUROPE, MIDDLE EAST & AFRICA ADULT VACCINES MARKET SIZE, BY HERPES ZOSTER, 2018-2032 (USD MILLION)
  • TABLE 258. EUROPE, MIDDLE EAST & AFRICA ADULT VACCINES MARKET SIZE, BY HPV, 2018-2032 (USD MILLION)
  • TABLE 259. EUROPE, MIDDLE EAST & AFRICA ADULT VACCINES MARKET SIZE, BY MENINGOCOCCAL, 2018-2032 (USD MILLION)
  • TABLE 260. EUROPE, MIDDLE EAST & AFRICA ADULT VACCINES MARKET SIZE, BY PNEUMOCOCCAL, 2018-2032 (USD MILLION)
  • TABLE 261. EUROPE, MIDDLE EAST & AFRICA ADULT VACCINES MARKET SIZE, BY TDAP, 2018-2032 (USD MILLION)
  • TABLE 262. EUROPE, MIDDLE EAST & AFRICA ADULT VACCINES MARKET SIZE, BY VACCINE TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 263. EUROPE, MIDDLE EAST & AFRICA ADULT VACCINES MARKET SIZE, BY DNA, 2018-2032 (USD MILLION)
  • TABLE 264. EUROPE, MIDDLE EAST & AFRICA ADULT VACCINES MARKET SIZE, BY MRNA, 2018-2032 (USD MILLION)
  • TABLE 265. EUROPE, MIDDLE EAST & AFRICA ADULT VACCINES MARKET SIZE, BY TOXOID, 2018-2032 (USD MILLION)
  • TABLE 266. EUROPE, MIDDLE EAST & AFRICA ADULT VACCINES MARKET SIZE, BY VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 267. EUROPE, MIDDLE EAST & AFRICA ADULT VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 268. EUROPE, MIDDLE EAST & AFRICA ADULT VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 269. EUROPE, MIDDLE EAST & AFRICA ADULT VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 270. EUROPE ADULT VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 271. EUROPE ADULT VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 272. EUROPE ADULT VACCINES MARKET SIZE, BY COVID 19, 2018-2032 (USD MILLION)
  • TABLE 273. EUROPE ADULT VACCINES MARKET SIZE, BY HEPATITIS, 2018-2032 (USD MILLION)
  • TABLE 274. EUROPE ADULT VACCINES MARKET SIZE, BY HERPES ZOSTER, 2018-2032 (USD MILLION)
  • TABLE 275. EUROPE ADULT VACCINES MARKET SIZE, BY HPV, 2018-2032 (USD MILLION)
  • TABLE 276. EUROPE ADULT VACCINES MARKET SIZE, BY MENINGOCOCCAL, 2018-2032 (USD MILLION)
  • TABLE 277. EUROPE ADULT VACCINES MARKET SIZE, BY PNEUMOCOCCAL, 2018-2032 (USD MILLION)
  • TABLE 278. EUROPE ADULT VACCINES MARKET SIZE, BY TDAP, 2018-2032 (USD MILLION)
  • TABLE 279. EUROPE ADULT VACCINES MARKET SIZE, BY VACCINE TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 280. EUROPE ADULT VACCINES MARKET SIZE, BY DNA, 2018-2032 (USD MILLION)
  • TABLE 281. EUROPE ADULT VACCINES MARKET SIZE, BY MRNA, 2018-2032 (USD MILLION)
  • TABLE 282. EUROPE ADULT VACCINES MARKET SIZE, BY TOXOID, 2018-2032 (USD MILLION)
  • TABLE 283. EUROPE ADULT VACCINES MARKET SIZE, BY VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 284. EUROPE ADULT VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 285. EUROPE ADULT VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 286. EUROPE ADULT VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 287. MIDDLE EAST ADULT VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 288. MIDDLE EAST ADULT VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 289. MIDDLE EAST ADULT VACCINES MARKET SIZE, BY COVID 19, 2018-2032 (USD MILLION)
  • TABLE 290. MIDDLE EAST ADULT VACCINES MARKET SIZE, BY HEPATITIS, 2018-2032 (USD MILLION)
  • TABLE 291. MIDDLE EAST ADULT VACCINES MARKET SIZE, BY HERPES ZOSTER, 2018-2032 (USD MILLION)
  • TABLE 292. MIDDLE EAST ADULT VACCINES MARKET SIZE, BY HPV, 2018-2032 (USD MILLION)
  • TABLE 293. MIDDLE EAST ADULT VACCINES MARKET SIZE, BY MENINGOCOCCAL, 2018-2032 (USD MILLION)
  • TABLE 294. MIDDLE EAST ADULT VACCINES MARKET SIZE, BY PNEUMOCOCCAL, 2018-2032 (USD MILLION)
  • TABLE 295. MIDDLE EAST ADULT VACCINES MARKET SIZE, BY TDAP, 2018-2032 (USD MILLION)
  • TABLE 296. MIDDLE EAST ADULT VACCINES MARKET SIZE, BY VACCINE TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 297. MIDDLE EAST ADULT VACCINES MARKET SIZE, BY DNA, 2018-2032 (USD MILLION)
  • TABLE 298. MIDDLE EAST ADULT VACCINES MARKET SIZE, BY MRNA, 2018-2032 (USD MILLION)
  • TABLE 299. MIDDLE EAST ADULT VACCINES MARKET SIZE, BY TOXOID, 2018-2032 (USD MILLION)
  • TABLE 300. MIDDLE EAST ADULT VACCINES MARKET SIZE, BY VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 301. MIDDLE EAST ADULT VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 302. MIDDLE EAST ADULT VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 303. MIDDLE EAST ADULT VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 304. AFRICA ADULT VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 305. AFRICA ADULT VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 306. AFRICA ADULT VACCINES MARKET SIZE, BY COVID 19, 2018-2032 (USD MILLION)
  • TABLE 307. AFRICA ADULT VACCINES MARKET SIZE, BY HEPATITIS, 2018-2032 (USD MILLION)
  • TABLE 308. AFRICA ADULT VACCINES MARKET SIZE, BY HERPES ZOSTER, 2018-2032 (USD MILLION)
  • TABLE 309. AFRICA ADULT VACCINES MARKET SIZE, BY HPV, 2018-2032 (USD MILLION)
  • TABLE 310. AFRICA ADULT VACCINES MARKET SIZE, BY MENINGOCOCCAL, 2018-2032 (USD MILLION)
  • TABLE 311. AFRICA ADULT VACCINES MARKET SIZE, BY PNEUMOCOCCAL, 2018-2032 (USD MILLION)
  • TABLE 312. AFRICA ADULT VACCINES MARKET SIZE, BY TDAP, 2018-2032 (USD MILLION)
  • TABLE 313. AFRICA ADULT VACCINES MARKET SIZE, BY VACCINE TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 314. AFRICA ADULT VACCINES MARKET SIZE, BY DNA, 2018-2032 (USD MILLION)
  • TABLE 315. AFRICA ADULT VACCINES MARKET SIZE, BY MRNA, 2018-2032 (USD MILLION)
  • TABLE 316. AFRICA ADULT VACCINES MARKET SIZE, BY TOXOID, 2018-2032 (USD MILLION)
  • TABLE 317. AFRICA ADULT VACCINES MARKET SIZE, BY VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 318. AFRICA ADULT VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 319. AFRICA ADULT VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 320. AFRICA ADULT VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 321. ASIA-PACIFIC ADULT VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 322. ASIA-PACIFIC ADULT VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 323. ASIA-PACIFIC ADULT VACCINES MARKET SIZE, BY COVID 19, 2018-2032 (USD MILLION)
  • TABLE 324. ASIA-PACIFIC ADULT VACCINES MARKET SIZE, BY HEPATITIS, 2018-2032 (USD MILLION)
  • TABLE 325. ASIA-PACIFIC ADULT VACCINES MARKET SIZE, BY HERPES ZOSTER, 2018-2032 (USD MILLION)
  • TABLE 326. ASIA-PACIFIC ADULT VACCINES MARKET SIZE, BY HPV, 2018-2032 (USD MILLION)
  • TABLE 327. ASIA-PACIFIC ADULT VACCINES MARKET SIZE, BY MENINGOCOCCAL, 2018-2032 (USD MILLION)
  • TABLE 328. ASIA-PACIFIC ADULT VACCINES MARKET SIZE, BY PNEUMOCOCCAL, 2018-2032 (USD MILLION)
  • TABLE 329. ASIA-PACIFIC ADULT VACCINES MARKET SIZE, BY TDAP, 2018-2032 (USD MILLION)
  • TABLE 330. ASIA-PACIFIC ADULT VACCINES MARKET SIZE, BY VACCINE TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 331. ASIA-PACIFIC ADULT VACCINES MARKET SIZE, BY DNA, 2018-2032 (USD MILLION)
  • TABLE 332. ASIA-PACIFIC ADULT VACCINES MARKET SIZE, BY MRNA, 2018-2032 (USD MILLION)
  • TABLE 333. ASIA-PACIFIC ADULT VACCINES MARKET SIZE, BY TOXOID, 2018-2032 (USD MILLION)
  • TABLE 334. ASIA-PACIFIC ADULT VACCINES MARKET SIZE, BY VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 335. ASIA-PACIFIC ADULT VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 336. ASIA-PACIFIC ADULT VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 337. ASIA-PACIFIC ADULT VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 338. GLOBAL ADULT VACCINES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 339. ASEAN ADULT VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 340. ASEAN ADULT VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 341. ASEAN ADULT VACCINES MARKET SIZE, BY COVID 19, 2018-2032 (USD MILLION)
  • TABLE 342. ASEAN ADULT VACCINES MARKET SIZE, BY HEPATITIS, 2018-2032 (USD MILLION)
  • TABLE 343. ASEAN ADULT VACCINES MARKET SIZE, BY HERPES ZOSTER, 2018-2032 (USD MILLION)
  • TABLE 344. ASEAN ADULT VACCINES MARKET SIZE, BY HPV, 2018-2032 (USD MILLION)
  • TABLE 345. ASEAN ADULT VACCINES MARKET SIZE, BY MENINGOCOCCAL, 2018-2032 (USD MILLION)
  • TABLE 346. ASEAN ADULT VACCINES MARKET SIZE, BY PNEUMOCOCCAL, 2018-2032 (USD MILLION)
  • TABLE 347. ASEAN ADULT VACCINES MARKET SIZE, BY TDAP, 2018-2032 (USD MILLION)
  • TABLE 348. ASEAN ADULT VACCINES MARKET SIZE, BY VACCINE TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 349. ASEAN ADULT VACCINES MARKET SIZE, BY DNA, 2018-2032 (USD MILLION)
  • TABLE 350. ASEAN ADULT VACCINES MARKET SIZE, BY MRNA, 2018-2032 (USD MILLION)
  • TABLE 351. ASEAN ADULT VACCINES MARKET SIZE, BY TOXOID, 2018-2032 (USD MILLION)
  • TABLE 352. ASEAN ADULT VACCINES MARKET SIZE, BY VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 353. ASEAN ADULT VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 354. ASEA